Boston Scientific Corporation $BSX Shares Acquired by Concurrent Investment Advisors LLC

Key Points

• Concurrent Investment Advisors increased its Boston Scientific stake by 77% in the second quarter to 55,565 shares valued at $2.37 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific’s stock opened at $45.00, near its 52-week low, despite the company beating quarterly earnings and revenue estimates. The board also authorized a $5 billion share-repurchase program, while analysts maintain a “Moderate Buy” consensus with an average price target of $71.62.
• A cybersecurity incident has clouded the outlook: the company expects it will miss its 2026 sales-growth and EPS guidance, although manufacturing and shipping operations are recovering. Management has not yet issued a replacement forecast, leaving investors focused on the pace and financial impact of the recovery.

Concurrent Investment Advisors LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 77.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,565 shares of the medical equipment provider's stock after purchasing an additional 24,166 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Boston Scientific were worth $2,371,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Renaissance Group LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $28,064,000. Perigon Wealth Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd raised its position in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider's stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in Boston Scientific during the 2nd quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider's stock valued at $13,659,000 after purchasing an additional 28,961 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 5.9%

Boston Scientific stock opened at $45.00 on Wednesday. The stock's 50 day moving average price is $47.04 and its 200 day moving average price is $55.18. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a market cap of $65.22 billion, a PE ratio of 18.22, a price-to-earnings-growth ratio of 1.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business's revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its shares are undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption and support a gradual rebound in revenue and profitability. The company also expects multiple product launches and cost savings to aid longer-term growth. Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided a replacement forecast, leaving investors without clear visibility into the size or duration of the financial impact. Management’s ability to restore systems and normalize shipments will be key near-term catalysts. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and earnings-per-share guidance ranges, including its previously issued third-quarter and full-year outlook. That reversal is driving the stock’s decline because it signals weaker near-term revenue, profit and cash-flow expectations. Boston Scientific Won't Meet Guidance Due to Cyberattack
• Negative Sentiment: The incident adds operational and execution risk to pressure already affecting parts of the portfolio, including WATCHMAN and electrophysiology products. Investors are now likely to focus on the timing of the recovery, the ultimate size of the earnings shortfall and whether customer orders can be fully restored. Boston Scientific's 2026 Growth Outlook Weakens

Insider Activity

In other news, Director David C. Habiger bought 2,100 shares of the firm's stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wolfe Research downgraded shares of Boston Scientific from an "outperform" rating to a "peer perform" rating in a research note on Friday, May 29th. Weiss Ratings cut Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Citigroup decreased their price target on Boston Scientific from $70.00 to $61.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Finally, Needham & Company LLC dropped their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a research note on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.